Drugbank Logo

Showing drug card for Estramustine (DB01196)

Legend: drug field target field enzyme field

for drugs
Version 2.5
Creation Date 2005-06-13 13:24:05
Update Date 2009-06-23 18:07:04
Primary Accession Number DB01196
Secondary Accession Number
  • APRD00625
Name Estramustine
Drug Type
  • Approved
  • Small Molecule
Description A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. [PubChem]
Synonyms
  1. Estramustin Sodium Phosphate
  2. Estramustina [INN-Spanish]
  3. Estramustine Sodium Phosphate
  4. Estramustinum [INN-Latin]
Brand Names
  1. Emcyt
  2. Estracyt
Brand Mixtures Not Available
Chemical IUPAC Name (17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl) N,N-bis(2-chloroethyl)carbamate
Chemical Formula C23H31Cl2NO3
Chemical Structure Structure
CAS Registry Number 2998-57-4
InChI Identifier InChI=1/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3
InChI Key FRPJXPJMRWBBIH-UHFFFAOYAO
KEGG Drug D04066 Link Image
KEGG Compound C11228 Link Image
PubChem Compound 18140 Link Image
PubChem Substance 161211 Link Image
ChEBI ID Not Available
PharmGKB ID Not Available
HET ID Not Available
GenBank ID Not Available
Drug ID Number [DIN] 02063794 Link Image
RxList Link http://www.rxlist.com/cgi/generic2/estramustine.htm Link Image
PDRhealth Link Not Available
Wikipedia Link http://en.wikipedia.org/wiki/Estramustine Link Image
FDA Label Not Available
Material Safety Data Sheet (MSDS) Not Available
Synthesis Reference Not Available
Average Molecular Weight 440.4030
Monoisotopic Molecular Weight 439.1681
State Solid
Melting Point 104.5 oC
Experimental Water Solubility Not Available Source: PhysProp
Predicted Water Solubility 3.85e-04 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity 5.7 Source: PhysProp
Predicted LogP 4.97 Calculated using ALOGPS
Experimental LogS Not Available
Predicted LogS -6.06 Calculated using ALOGPS
Experimental Caco2 Permeability Not Available
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Show Link Image | Download Link Image
SDF File Show Link Image | Download Link Image
PDB File Show Link Image | Download Link Image
2D Structure
3D Structure
Experimental PDB ID Not Available
Isomeric SMILES C[C@]12CC[C@H]3[C@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@H]2O
Canonical SMILES CC12CCC3C(CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)C1CCC2O
Drug Category
  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Hormonal
  • Radiation-Protective Agents
ATC Codes
AHFS Codes
  • 10:00.00
Indication For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
Pharmacology Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nornitrogen mustard. The precise mechanism of action of estramustine is unknown. Unlike other alkylating agents, estramustine does not directly damage DNA.
Mechanism of Action The precise mechanism of action of estramustine is unknown.
Absorption Not Available
Toxicity Not Available
Protein Binding Not Available
Biotransformation Not Available
Half Life 20 hours
Dosage Forms
Form Route
Capsule Oral
Patient Information Not Available
Contraindications Show Link Image
Interactions Show Link Image
Drug Interactions
Drug Interaction
Clodronate Clodronate increases the levels of estramustine
Food Interactions
  • Do not take with milk or milk products.
  • Take on an empty stomach.
Pathways Not Available
General References
  1. Drugs.com Link Image
  2. Wikipedia Link Image
  3. RxList Link Image
Organisms Affected
  • Humans and other mammals
Targets
  1. Estrogen receptor
  2. Estrogen receptor beta
  3. Multidrug resistance protein 1
  4. Microtubule-associated protein 2
  5. Microtubule-associated protein 1A
Drug Target 1 [top]
Target 1 ID 136
Target 1 Name Estrogen receptor
Target 1 Synonyms
  1. ER
  2. ER-alpha
  3. Estradiol receptor
Target 1 Gene Name ESR1
Target 1 Protein Sequence >Estrogen receptor 
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV
Target 1 Number of Residues 604
Target 1 Molecular Weight 66217
Target 1 Theoretical pI 8.14
Target 1 GO Classification
Function
ion binding
cation binding
transition metal ion binding
zinc ion binding
steroid binding
signal transducer activity
receptor activity
ligand-dependent nuclear receptor activity
steroid hormone receptor activity
binding
nucleic acid binding
DNA binding
transcription factor activity
Process
regulation of biological process
regulation of physiological process
regulation of metabolism
regulation of cellular metabolism
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
regulation of transcription
regulation of transcription, DNA-dependent
Component
organelle
membrane-bound organelle
intracellular membrane-bound organelle
nucleus
Target 1 General Function Involved in transcription factor activity
Target 1 Specific Function Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues
Target 1 Pathways Not Available
Target 1 Reactions Not Available
Target 1 Pfam Domain Function
Target 1 Signals
  • None
Target 1 Transmembrane Regions
  • None
Target 1 Essentiality Non-Essential
Target 1 GenBank ID Protein 31234 Link Image
Target 1 UniProtKB/Swiss-Prot ID P03372 Link Image
Target 1 UniProtKB/Swiss-Prot Entry Name ESR1_HUMAN Link Image
Target 1 PDB ID 1R5K Link Image
Target 1 PDB File Show
Target 1 3D Structure
Target 1 Cellular Location
  • Nucleus
Target 1 Gene Sequence >1788 bp 
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG
AACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC
GAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC
GAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC
GGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC
AACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG
GTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT
GGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG
GAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG
TCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC
CGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA
GGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG
GGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC
TCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG
GATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT
TCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG
GCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA
TGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGTG
AAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC
ATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG
CAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA
TTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC
AAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG
CACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA
GGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG
CTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA
AAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACAGTCTGA
Target 1 GenBank Gene ID
Target 1 GeneCard ID ESR1 Link Image
Target 1 GenAtlas ID ESR1 Link Image
Target 1 HGNC ID HGNC:3467 Link Image
Target 1 Chromosome Location 6
Target 1 Locus 6q25.1
Target 1 SNPs SNPJam Report Link Image
Target 1 General References
  1. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52. [PubMed Link Image]
  2. Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999 Aug 6;274(32):22296-302. [PubMed Link Image]
  3. Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem. 1999 Nov 26;274(48):34283-93. [PubMed Link Image]
  4. Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7. [PubMed Link Image]
  5. Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53. [PubMed Link Image]
  6. Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol. 2002 May;22(10):3358-72. [PubMed Link Image]
  7. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1. [PubMed Link Image]
  8. Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11. [PubMed Link Image]
  9. Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem. 1992 May 15;267(14):9868-73. [PubMed Link Image]
  10. Schwabe JW, Neuhaus D, Rhodes D: Solution structure of the DNA-binding domain of the oestrogen receptor. Nature. 1990 Nov 29;348(6300):458-61. [PubMed Link Image]
  11. 2792078 Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989 Jul;8(7):1981-6.
  12. 3753802 Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 7;231(4742):1150-4.
  13. 3754034 Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986 Mar 13-19;320(6058):134-9.
  14. 7476978 Joel PB, Traish AM, Lannigan DA: Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol. 1995 Aug;9(8):1041-52.
  15. 7539106 Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995 Jan;9(1):24-33.
  16. 7838153 Arnold SF, Obourn JD, Jaffe H, Notides AC: Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994 Sep;8(9):1208-14.
  17. 7916651 Pfeffer U, Fecarotta E, Castagnetta L, Vidali G: Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res. 1993 Feb 15;53(4):741-3.
  18. 8221895 Schwabe JW, Chapman L, Finch JT, Rhodes D: The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 1993 Nov 5;75(3):567-78.
  19. 8600466 Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC: A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962-9.
  20. 8961262 McInerney EM, Ince BA, Shapiro DJ, Katzenellenbogen BS: A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. Mol Endocrinol. 1996 Dec;10(12):1519-26.
  21. 9195227 Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Moller P, Stratton MR, Borresen-Dale AL: Screening for ESR mutations in breast and ovarian cancer patients. Hum Mutat. 1997;9(6):531-6.
  22. 9338790 Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16;389(6652):753-8.
  23. 9600906 Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A. 1998 May 26;95(11):5998-6003.
  24. 9619507 Maalouf GJ, Xu W, Smith TF, Mohr SC: Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dyn. 1998 Apr;15(5):841-51.
  25. 9875847 Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37.
Target 1 Drug References
  1. Ferno M, Borg A, Ingvar C, Jonsson PE: Estrogen receptor and binding site for estramustine in metastatic malignant melanoma. Anticancer Res. 1987 Jul-Aug;7(4B):741-3. [PubMed Link Image]
  2. Yoshizumi N: [The effects of site-directed chemotherapy due to E2 as a drug carrier to the human endometrial adenocarcinoma cells in vitro] Nippon Sanka Fujinka Gakkai Zasshi. 1985 Apr;37(4):637-45. [PubMed Link Image]
  3. von Schoultz E, Carlstrom K, Henriksson R, Lagerlof B, Hansson J: Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5. [PubMed Link Image]
Drug Target 2 [top]
Target 2 ID 869
Target 2 Name Estrogen receptor beta
Target 2 Synonyms
  1. ER-beta
Target 2 Gene Name ESR2
Target 2 Protein Sequence >Estrogen receptor beta 
MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPS
NVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARSLEHTLPVN
RETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGH
NDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLH
CAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTK
LADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDL
VLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDA
DSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMK
CKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ
Target 2 Number of Residues 538
Target 2 Molecular Weight 59217
Target 2 Theoretical pI 8.55
Target 2 GO Classification
Function
ion binding
cation binding
transition metal ion binding
zinc ion binding
steroid binding
signal transducer activity
receptor activity
ligand-dependent nuclear receptor activity
steroid hormone receptor activity
binding
nucleic acid binding
DNA binding
transcription factor activity
Process
regulation of biological process
regulation of physiological process
regulation of metabolism
regulation of cellular metabolism
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
regulation of transcription
regulation of transcription, DNA-dependent
Component
organelle
membrane-bound organelle
intracellular membrane-bound organelle
nucleus
Target 2 General Function Involved in transcription factor activity
Target 2 Specific Function Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner. Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA- binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual
Target 2 Pathways Not Available
Target 2 Reactions Not Available
Target 2 Pfam Domain Function
Target 2 Signals
  • None
Target 2 Transmembrane Regions
  • None
Target 2 Essentiality Non-Essential
Target 2 GenBank ID Protein 2911152 Link Image
Target 2 UniProtKB/Swiss-Prot ID Q92731 Link Image
Target 2 UniProtKB/Swiss-Prot Entry Name ESR2_HUMAN Link Image
Target 2 PDB ID 1QKM Link Image
Target 2 PDB File Show
Target 2 3D Structure
Target 2 Cellular Location
  • Nucleus
Target 2 Gene Sequence >1593 bp 
ATGGATATAAAAAACTCACCATCTAGCCTTAATTCTCCTTCCTCCTACAACTGCAGTCAA
TCCATCTTACCCCTGGAGCACGGCTCCATATACATACCTTCCTCCTATGTAGACAGCCAC
CATGAATATCCAGCCATGACATTCTATAGCCCTGCTGTGATGAATTACAGCATTCCCAGC
AATGTCACTAACTTGGAAGGTGGGCCTGGTCGGCAGACCACAAGCCCAAATGTGTTGTGG
CCAACACCTGGGCACCTTTCTCCTTTAGTGGTCCATCGCCAGTTATCACATCTGTATGCG
GAACCTCAAAAGAGTCCCTGGTGTGAAGCAAGATCGCTAGAACACACCTTACCTGTAAAC
AGAGAGACACTGAAAAGGAAGGTTAGTGGGAACCGTTGCGCCAGCCCTGTTACTGGTCCA
GGTTCAAAGAGGGATGCTCACTTCTGCGCTGTCTGCAGCGATTACGCATCGGGATATCAC
TATGGAGTCTGGTCGTGTGAAGGATGTAAGGCCTTTTTTAAAAGAAGCATTCAAGGACAT
AATGATTATATTTGTCCAGCTACAAATCAGTGTACAATCGATAAAAACCGGCGCAAGAGC
TGCCAGGCCTGCCGACTTCGGAAGTGTTACGAAGTGGGAATGGTGAAGTGTGGCTCCCGG
AGAGAGAGATGTGGGTACCGCCTTGTGCGGAGACAGAGAAGTGCCGACGAGCAGCTGCAC
TGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAGCTGCTGCTG
GACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCTGAGCCGCCCCATGTG
CTGATCAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGTCCCTGACCAAG
TTGGCCGACAAGGAGTTGGTACACATGATCAGCTGGGCCAAGAAGATTCCCGGCTTTGTG
GAGCTCAGCCTGTTCGACCAAGTGCGGCTCTTGGAGAGCTGTTGGATGGAGGTGTTAATG
ATGGGGCTGATGTGGCGCTCAATTGACCACCCCGGCAAGCTCATCTTTGCTCCAGATCTT
GTTCTGGACAGGGATGAGGGGAAATGCGTAGAAGGAATTCTGGAAATCTTTGACATGCTC
CTGGCAACTACTTCAAGGTTTCGAGAGTTAAAACTCCAACACAAAGAATATCTCTGTGTC
AAGGCCATGATCCTGCTCAATTCCAGTATGTACCCTCTGGTCACAGCGACCCAGGATGCT
GACAGCAGCCGGAAGCTGGCTCACTTGCTGAACGCCGTGACCGATGCTTTGGTTTGGGTG
ATTGCCAAGAGCGGCATCTCCTCCCAGCAGCAATCCATGCGCCTGGCTAACCTCCTGATG
CTCCTGTCCCACGTCAGGCATGCGAGTAACAAGGGCATGGAACATCTGCTCAACATGAAG
TGCAAAAATGTGGTCCCAGTGTATGACCTGCTGCTGGAGATGCTGAATGCCCACGTGCTT
CGCGGGTGCAAGTCCTCCATCACGGGGTCCGAGTGCAGCCCGGCAGAGGACAGTAAAAGC
AAAGAGGGCTCCCAGAACCCACAGTCTCAGTGA
Target 2 GenBank Gene ID
Target 2 GeneCard ID ESR2 Link Image
Target 2 GenAtlas ID ESR2 Link Image
Target 2 HGNC ID HGNC:3468 Link Image
Target 2 Chromosome Location 14
Target 2 Locus 14q23.2
Target 2 SNPs SNPJam Report Link Image
Target 2 General References
  1. Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA: Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem. 2000 Feb 25;275(8):5308-17. [PubMed Link Image]
  2. Li LC, Yeh CC, Nojima D, Dahiya R: Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun. 2000 Aug 28;275(2):682-9. [PubMed Link Image]
  3. Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53. [PubMed Link Image]
  4. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1. [PubMed Link Image]
  5. Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996 Aug 19;392(1):49-53. [PubMed Link Image]
  6. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997 Aug 8;90(3):569-80. [PubMed Link Image]
  7. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S: Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem. 1997 Oct 10;272(41):25832-8. [PubMed Link Image]
  8. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998 Feb 4;243(1):122-6. [PubMed Link Image]
  9. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998 Jun 9;247(1):75-8. [PubMed Link Image]
  10. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res. 1998 Aug 1;26(15):3505-12. [PubMed Link Image]
  11. 9685228 Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC, Watson PH: Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol. 1998 Mar 16;138(1-2):199-203.
Target 2 Drug References
  1. Ho SM: Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004 Feb 15;91(3):491-503. [PubMed Link Image]
Drug Target 3 [top]
Target 3 ID 1588
Target 3 Name Multidrug resistance protein 1
Target 3 Synonyms
  1. ATP-binding cassette sub-family B member 1
  2. CD243 antigen
  3. EC 3.6.3.44
  4. P-glycoprotein 1
Target 3 Gene Name ABCB1
Target 3 Protein Sequence >Multidrug resistance protein 1 
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ
Target 3 Number of Residues 1301
Target 3 Molecular Weight 141464
Target 3 Theoretical pI 9.44
Target 3 GO Classification
Function
ATPase activity
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
ATPase activity, coupled to transmembrane movement of substances
purine nucleotide binding
adenyl nucleotide binding
ATP binding
catalytic activity
hydrolase activity
hydrolase activity, acting on acid anhydrides
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides
pyrophosphatase activity
nucleoside-triphosphatase activity
binding
nucleotide binding
Process
physiological process
cellular physiological process
transport
Component
cell
membrane
intrinsic to membrane
integral to membrane
Target 3 General Function Defense mechanisms and drug export
Target 3 Specific Function Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells
Target 3 Pathways Not Available
Target 3 Reactions
  • ATP + H2O + xenobioticin = ADP + phosphate + xenobioticout
Target 3 Pfam Domain Function
Target 3 Signals
  • None
Target 3 Transmembrane Regions
  • 52-72
  • 120-140
  • 189-209
  • 216-236
  • 297-317
  • 326-346
  • 711-731
  • 757-777
  • 833-853
  • 854-874
  • 937-957
  • 974-994
Target 3 Essentiality Non-Essential
Target 3 GenBank ID Protein 307180 Link Image
Target 3 UniProtKB/Swiss-Prot ID P08183 Link Image
Target 3 UniProtKB/Swiss-Prot Entry Name MDR1_HUMAN Link Image
Target 3 PDB ID Not Available
Target 3 Cellular Location
  • Membrane
  • multi-pass membrane protein
Target 3 Gene Sequence >3843 bp 
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT
AAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA
Target 3 GenBank Gene ID
Target 3 GeneCard ID ABCB1 Link Image
Target 3 GenAtlas ID ABCB1 Link Image
Target 3 HGNC ID HGNC:40 Link Image
Target 3 Chromosome Location 7
Target 3 Locus 7q21.1
Target 3 SNPs SNPJam Report Link Image
Target 3 General References
  1. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. [PubMed Link Image]
  2. Decleves X, Chevillard S, Charpentier C, Vielh P, Laplanche JL: A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum Mutat. 2000 May;15(5):486. [PubMed Link Image]
  3. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001 Mar;69(3):169-74. [PubMed Link Image]
  4. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001 Feb;2(1):51-64. [PubMed Link Image]
  5. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet. 2002;47(1):38-50. [PubMed Link Image]
  6. Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64. [PubMed Link Image]
  7. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990 Jan 5;265(1):506-14. [PubMed Link Image]
  8. Gekeler V, Weger S, Probst H: mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem Biophys Res Commun. 1990 Jun 15;169(2):796-802. [PubMed Link Image]
  9. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K: P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun. 1989 Jul 14;162(1):224-31. [PubMed Link Image]
  10. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381-9. [PubMed Link Image]
  11. 2897240 Choi KH, Chen CJ, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 1988 May 20;53(4):519-29.
  12. 9038218 Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C, Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997 Feb 28;272(9):5974-82.
  13. 9473242 Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998 Mar 1;91(5):1749-56.
Target 3 Drug References
  1. Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP: A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003 Feb 1;97(3):537-44. [PubMed Link Image]
  2. Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD: Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer. 1995 May 15;75(10):2597-604. [PubMed Link Image]
  3. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD: P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 1994 May 4;86(9):688-94. [PubMed Link Image]
  4. Yang CP, Shen HJ, Horwitz SB: Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst. 1994 May 4;86(9):723-5. [PubMed Link Image]
Drug Target 4 [top]
Target 4 ID 1852
Target 4 Name Microtubule-associated protein 2
Target 4 Synonyms
  1. MAP 2
  2. MAP-2
Target 4 Gene Name MAP2
Target 4 Protein Sequence >Microtubule-associated protein 2 
MADERKDEGKAPHWTSAPLTEASAHSHPPEIKDQGGAGEGLVRSANGFPYREDEEGAFGE
HGSQGTYSNTKENGINGELTSADRETAEEVSARIVQVVTAEAVAVLKGEQEKEAQHKDQT
AALPLAAEETANLPPSPPPSPASEQTVTVEEDLLTASKMEFHDQQELTPSTAEPSDQKEK
ESEKQSKPGEDLKHAALVSQPETTKTYPDKKDMQGTEEEKAPLALFGHTLVASLEDMKQK
TEPSLVVPGIDLPKEPPTPKEQKDWFIEMPTEAKKDEWGLVAPISPGPLTPMREKDVFDD
IPKWEGKQFDSPMPSPFQGGSFTLPLDVMKNEIVTETSPFAPAFLQPDDKKSLQQTSGPA
TAKDSFKIEEPHEAKPDKMAEAPPSEAMTLPKDAHIPVVEEHVMGKVLEEEKEAINQETV
QQRDTFTPSGQEPILTEKETELKLEEKTTISDKEAVPKESKPPKPADEEIGIIQTSTEHT
FSEQKDQEPTTDMLKQDSFPVSLEQAVTDSAMTSKTLEKAMTEPSALIEKSSIQELFEMR
VDDKDKIEGVGAATSAELDMPFYEDKSGMSKYFETSALKEEATKSIEPGSDYYELSDTRE
SVHESIDTMSPMHKNGDKEFQTGKESQPSPPAQEAGYSTLAQSYPSDLPEEPSSPQERMF
TIDPKVYGEKRDLHSKNKDDLTLSRSLGLGGRSAIEQRSMSINLPMSCLDSIALGFNFGR
GHDLSPLASDILTNTSGSMDEGDDYLPATTPALEKAPCFPVESKEEEQIEKVKATGEEST
QAEISCESPFLAKDFYKNGTVMAPDLPEMLDLAGTRSRLASVSADAEVARRKSVPSETVV
EDSRTGLPPVTDENHVIVKTDSQLEDLGYCVFNKYTVPLPSPVQDSENLSGESGTFYEGT
DDKVRRDLATDLSLIEVKLAAAGRVKDEFSVDKEASAHISGDKSGLSKEFDQEKKANDRL
DTVLEKSEEHADSKEHAKKTEEAGDEIETFGLGVTYEQALAKDLSIPTDASSEKAEKGLS
SVPEIAEVEPSKKVEQGLDFAVQGQLDVKISDFGQMASGLNIDDRRATELKLEATQDMTP
SSKAPQEADAFMGVESGHMKEGTKVSETEVKQKVAKPDLVHQEAVDKEESYESSGEHESL
TMESLKADEGKKETSPESSLIQDEIAVKLSVEIPCPPAVSEADLATDERADVQMEFIQGP
KEESKETPDISITPSDVAEPLHETIVSEPAEIQSEEEEIEAQGEYDKLLFRSDTLQITDL
GVSGAREEFVETCPSEHKGVIESVVTIEDDFITVVQTTTDEGESGSHSVRFAALEQPEVE
RRPSPHDEEEFEVEEAAEAQAEPKDGSPEAPASPEREEVALSEYKTETYDDYKDETTIDD
SIMDADSLWVDTQDDDRSIMTEQLETIPKEEKAEKEARRSSLEKHRKEKPFKTGRGRIST
PERKVAKKEPSTVSRDEVRRKKAVYKKAELAKKTEVQAHSPSRKFILKPAIKYTRPTHLS
CVKRKTTAAGGESALAPSVFKQAKDKVSDGVTKSPEKRSSLPRPSSILPPRRGVSGDRDE
NSFSLNSSISSSARRTTRSEPIRRAGKSGTSTPTTPGSTAITPGTPPSYSSRTPGTPGTP
SYPRTPHTPGTPKSAILVPSEKKVAIIRTPPKSPATPKQLRLINQPLPDLKNVKSKIGST
DNIKYQPKGGQVQIVTKKIDLSHVTSKCGSLKNIRHRPGGGRVKIESVKLDFKEKVQAKV
GSLDNAHHVPGGGNVKIDSQKLNFREHAKARVDHGAEIITQSPGRSSVASPRRLSNVSSS
GSINLLESPQLATLAEDVTAALAKQGL
Target 4 Number of Residues 1857
Target 4 Molecular Weight 199540
Target 4 Theoretical pI 4.55
Target 4 GO Classification
Function
Not Available
Process
regulation of biological process
regulation of physiological process
regulation of cellular physiological process
regulation of cell organization and biogenesis
regulation of microtubule polymerization or depolymerization
negative regulation of microtubule polymerization or depolymerization
negative regulation of microtubule depolymerization
Component
Not Available
Target 4 General Function Cell motility
Target 4 Specific Function The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules
Target 4 Pathways Not Available
Target 4 Reactions Not Available
Target 4 Pfam Domain Function
Target 4 Signals
  • None
Target 4 Transmembrane Regions
  • None
Target 4 Essentiality Non-Essential
Target 4 GenBank ID Protein 409875 Link Image
Target 4 UniProtKB/Swiss-Prot ID P11137 Link Image
Target 4 UniProtKB/Swiss-Prot Entry Name MAP2_HUMAN Link Image
Target 4 PDB ID Not Available
Target 4 Cellular Location Not Available
Target 4 Gene Sequence >5481 bp 
ATGGCAGATGAACGGAAAGACGAAGCAAAGGCACCTCACTGGACCTCAGCACCGCTAACA
GAGGCATCTGCACACTCACATCCACCTGAGATTAAGGATCAAGGCGGACGAGGGGAAGGA
CTTGTCCGAAGCGCCAATGGATTCCCATACAGGGAGGATGAAGAGGGTGCCTTTGGAGAG
CATGGGTCACAGGGCACCTATTCAAATACCAAAGAGAATGGGATCAACGGAGAGCTGACC
TCAGCTGACAGAGAAACAGCAGAGGAGGTGTCTGCAAGGATAGTTCAAGTAGTCACTGCT
GAGGCTGTAGCAGTCCTGAAAGCTGAACAAGAGAAAGAAGCTCAACATAAAGACCAGACT
GCAGCTCTGCCTTTAGCAGCTGAAGAAACAGCTAATCTGCCTCCTTCTCCACCCCCATCA
CCTGCCTCAGAACAGACTGTCACAGTGGAGGAAGATTTACTTACAGCCTCGAAGATGGAG
TTCCACGATCAACAGGAATTGACTCCCTCTACAGCTGAGCCTTCAGACCAGAAGGAAAAG
GAGTCAGAGAAGCAAAGTAGTCCTGGTGAAGACCTTAAACATGCTGCCTTAGTTTCTCAG
CCAGAGACAACTAAAACTTACCCTGATAAAAAGGACATGCAAGGCACAGAAGAAGAAAAA
GCACCCCTAGCTTTGTTTGGGCACACTCTTGTTGCCAGCCTGGAAGACATGAAACAGAAG
ACAGAACCAAGCCTTGTAGTACCTGGCATTGACCTCCCTAAAGAGCCTCCAACTCCAAAA
GAACAAAAGGACTGGTTCATCGAAATGCCAACGGAAGCAAAAAAGGATGAGTGGGGTTTA
GTTGCCCCCATATCTCCTGGCCCTCTGACTCCCATGAGGGAAAAAGATGTATTTGATGAT
ATCCCAAAATGGGAAGGGAAACAGTTTGATTCTCCCATGCCAAGTCCCTTTCAAGGGGGA
AGCTTCACTCTTCCTTTAGATGTCATGAAGAATGAAATAGTTACAGAAACATCGCCCTTT
GCCCCTGCCTTTTTACAGCCAGATGACAAAAAATCTCTGCAACAAACCAGTGGCCCAGCT
ACTGCCAAAGATAGTTTTAAAATTGAAGAGCCCCATGAGGCTAAACCTGACAAAATGGCA
GAAGCACCACCCTCAGAGGCAATGACCTTACCCAAAGATGCTCACATTCCAGTTGTAGAA
GAACATGTTATGGGGAAAGTTTTAGAGGAAGAAAAGGAGGCCATAAATCAAGAGACTGTG
CAGCAAAGGGATACTTTCACCCCCAGTGGACAGGAACCTATACTTACTGAAAAGGAAACT
GAGCTGAAGCTTGAAGAAAAAACCACCATTTCTGACAAAGAAGCTGTGCCAAAAGAGAGT
AAACCCCCAAAACCTGCAGATGAAGAAATAGGCATAATTCAGACCTCCACAGAGCACACT
TTCTCAGAACAGAAAGACCAAGAGCCTACCACAGATATGTTGAAACAGGACTCGTTCCCT
GTAAGTTTGGAGCAAGCAGTTACAGATTCAGCCATGACCTCTAAAACACTGGAGAAAGCC
ATGACCGAACCATCTGCATTAATTGAAAAGAGCTCAATTCAGGAACTTTTTGAAATGAGA
GTTGATGACAAAGATAAGATTGAAGGAGTTGGAGCTGCAACATCAGCTGAGCTTGATATG
CCATTTTATGAAGATAAATCAGGAATGTCCAAGTACTTTGAAACATCTGCCTTGAAAGAA
GAAGCAACAAAAAGCATTGAGCCAGGCAGTGATTACTATGAACTGAGTGACACTAGAGAA
AGTGTCCATGAGTCTATTGATACCATGTCTCCCATGCATAAAAATGGTGACAAGGAGTTT
CAAACAGGAAAAGAATCCCAGCCCAGTCCTCCAGCACAAGAAGCAGGGTACAGCACTCTC
GCACAGAGTTATCCATCAGATTTACCTGAAGAACCCAGTTCTCCTCAAGAAAGAATGTTC
ACTATTGATCCAAAAGTGTATGGAGAGAAAAGGGACCTCCACAGTAAGAATAAGGATGAT
TTGACCCTTAGCAGGAGTTTAGGACTTGGTGGTAGGTCTGCAATAGAACAAAGAAGCATG
TCAATCAATTTGCCGATGTCTTGCCTAGATTCCATAGCCCTTGGATTTAACTTTGGTCGG
GGACATGATCTTTCTCCTCTGGCTTCCGATATTCTAACCAACACTAGTGGAAGTATGGAT
GAAGGGGATGATTACCTTCCAGCCACCACACCTGCACTGGAGAAAGCCCCTTGCTTCCCT
GTAGAAAGCAAAGAGGAAGAACAGATAGAGAAAGTAAAAGCTACTGGAGAAGAAAGTACT
CAAGCGGAGATATCATGTGAGTCTCCTTTCCTAGCCAAAGATTTTTACAAAAATGGTACT
GTCATGGCACCTGACCTTCCTGAAATGCTAGATCTGGCAGGCACAAGGTCAAGATTGGCT
TCTGTGAGTGCAGATGCTGAGGTTGCCAGGAGGAAATCAGTCCCATCAGAGACTGTGGTT
GAGGATAGTCGTACTGGCTTGCCCCCGGTAACTGATGAAAACCATGTCATTGTAAAAACG
GACAGTCAGCTCGAAGACCTGGGCTACTGTGTGTTCAATAAGTACACAGTCCCATTGCCA
TCACCTGTTCAAGACAGTGAGAATTTATCAGGGGAGAGTGGTACCTTTTACGAAGGCACT
GATGATAAAGTTCGAAGAGATTTGGCCACAGACCTTTCACTGATTGAAGTGAAACTGGCA
GCAGCCGGAAGAGTCAAAGATGAGTTCAGTGTTGACAAAGAAGCATCCGCGCATATCTCT
GGTGACAAATCAGGACTGAGTAAGGAGTTTGACCAAGAGAAGAAAGCTAATGATAGGTTG
GATACTGTACTAGAAAAGAGTGAAGAACATGCTGATTCAAAAGAACATGCCAAGAAAACT
GAAGAGGCTGGTGATGAAATAGAAACATTCGGATTAGGAGTAACCTATGAGCAAGCTTTG
GCCAAAGATTTGTCAATACCAACAGATGCATCCTCTGAGAAAGCAGAGAAGGGTCTTAGT
TCAGTTCCAGAGATAGCTGAGGTAGAACCATCCAAAAAGGTGGAACAAGGTCTGGATTTT
GCTGTCCAGGGTCAACTAGATGTTAAAATTAGTGACTTTGGACAGATGGCTTCAGGGCTA
AACATAGATGATAGAAGGGCAACAGAGCTAAAACTTGAGGCTACACAGGACATGACCCCC
TCATCCAAAGCACCGCAGGAGGCAGATGCATTTATGGGTGTTGAGTCTGGCCACATGAAA
GAAGGCACTAAAGTTAGTGAGACAGAAGTCAAACAGAAGGTGGCCAAGCCTGACTTGGTG
CACCAGGAGGCTGTAGACAAGGAGGAGTCCTATGAATCTAGTGGTGAGCATGAAAGTCTC
ACCATGGAGTCCTTGAAAGCTGATGAGGGCAAGAAGGAAACATCTCCAGAATCATCTCTA
ATTCAAGATGAGATTGCCGTCAAATTGTCAGTGGAAATACCTTGCCCACCTGCTGTTTCA
GAGGCTGATTTAGCCACAGATGAGAGAGCTGATGTCCAGATGGAATTTATTCAGGGGCCA
AAAGAAGAAAGCAAAGAGACCCCAGATATATCCATCACGCCTTCTGATGTTGCAGAGCCA
TTGCATGAAACGATCGTATCTGAACCAGCAGAGATTCAGAGTGAGGAAGAAGAGATAGAA
GCCCAGGGAGAATATGATAAACTGCTCTTCCGCTCAGACACCCTTCAGATAACTGACCTG
GGTGTCTCAGGTGCCAGGGAGGAATTTGTGGAGACCTGCCCAAGTGAACACAAAGGAGTG
ATTGAGTCTGTTGTGACCATCGAGGATGATTTCATCACTGTAGTGCAAACCACAACTGAT
GAAGGGGAGTCAGGGTCCCACAGCGTGCGTTTTGCAGCCCTAGAGCAGCCTGAGGTGGAA
AGGAGACCATCTCCTCATGATGAAGAAGAGTTTGAAGTAGAAGAGGCAGCTGAAGCCCAG
GCAGAACCCAAAGATGGTTCCCCAGAGGCTCCAGCTTCCCCTGAGAGAGAAGAGGTTGCA
CTTTCTGAATATAAGACAGAAACCTATGACGATTACAAAGATGAGACCACCATTGACGAC
TCCATCATGGACGCTGACAGCCTCTGGGTGGACACTCAAGATGATGATAGGAGCATCATG
ACAGAACAGTTAGAAACTATTCCTAAAGAGGAGAAAGCTGAAAAGGAAGCTCGGAGATCA
TCTCTTGAGAAACATAGAAAAGAAAAGCCTTTTAAAACCGGGAGAGGCAGAATTTCCACT
CCTGAAAGAAAAGTAGCTAAAAAGGAACCTAGCACAGTCTCCAGAGATGAAGTGAGAAGG
AAAAAAGCAGTTTATAAGAAGGCTGAACTTGCTAAAAAAACAGAAGTTCAGGCCCACTCT
CCCTCCAGGAAATTCATTTTAAAACCTGCTATCAAATATACTAGACCAACTCATCTCTCC
TGTGTTAAGCGGAAAACCACAGCAGCAGGTGGGGAATCAGCTCTGGCTCCCAGTGTATTT
AAACAGGCAAAGGACAAAGTCTCTGACGGAGTAACCAAGAGCCCAGAAAAGCGCTCTTCT
CTCCCAAGACCTTCCTCCATTCTCCCTCCTCGGCGAGGTGTGTCAGGAGACAGAGATGAG
AATTCCTTCTCTCTCAACAGTTCTATCTCTTCTTCAGCACGGCGGACCACCAGGTCAGAG
CCAATTCGCAGAGCAGGAAAGAGTGGTACCTCAACACCCACTACCCCTGGGTCTACTGCC
ATCACTCCTGGCACCCCACCAAGTTATTCTTCACGCACACCAGGCACTCCTGGAACCCCT
AGCTATCCCAGGACCCCTCACACACCAGGAACCCCCAAGTCTGCCATCTTGGTGCCGAGT
GAGAAGAAGGTCGCCATCATACGTACTCCTCCAAAATCTCCTGCGACTCCCAAGCAGCTT
CGGCTTATTAACCAACCACTGCCAGACCTGAAGAATGTCAAATCCAAAATCGGATCAACA
GACAACATCAAATACCAGCCTAAAGGGGGGCAGGTACAAATTGTTACCAAGAAAATAGAC
CTAAGCCATGTGACATCCAAATGTGGCTCTCTGAAGAACATCGACAGGCCAGGTGGCGGA
CGTGTGAAAATTGAGAGTGTAAAACTAGATTTCAAGGAAAAGGTCCAAGCTAAAGTTGGT
TCTCTTGATAATGCTCATCATGTACCTGGAGGTGGTAATGTCAAGATTGACAGCCAAAAG
TTGAACTTCAGAGAGCATGCTAAAGCCCGTGTGGACCATGGGGCTGAGATCATTACACAG
TCCCCAGGCAGATCCAGCGTGGCATCACCCCGACGACTCAGCAATGTCTCCTCGTCTGGA
AGCATCAACCTGCTCGAATCTCCTCAGCTTGCCACTTTGGCTGAGGATGTCACTGCTGCA
CTCGCTAAGCAGGGCTTGTGA
Target 4 GenBank Gene ID
Target 4 GeneCard ID MAP2 Link Image
Target 4 GenAtlas ID MAP2 Link Image
Target 4 HGNC ID HGNC:6839 Link Image
Target 4 Chromosome Location 2
Target 4 Locus 2q34-q35
Target 4 SNPs SNPJam Report Link Image
Target 4 General References
  1. Kosik KS, Orecchio LD, Bakalis S, Duffy L, Neve RL: Partial sequence of MAP2 in the region of a shared epitope with Alzheimer neurofibrillary tangles. J Neurochem. 1988 Aug;51(2):587-98. [PubMed Link Image]
  2. Dammerman M, Yen SH, Shafit-Zagardo B: Sequence of a human MAP-2 region sharing epitopes with Alzheimer neurofibrillary tangles. J Neurosci Res. 1989 Dec;24(4):487-95. [PubMed Link Image]
  3. Albala JS, Kalcheva N, Shafit-Zagardo B: Characterization of the transcripts encoding two isoforms of human microtubule-associated protein-2 (MAP-2). Gene. 1993 Dec 22;136(1-2):377-8. [PubMed Link Image]
Target 4 Drug References
  1. Moraga D, Rivas-Berrios A, Farias G, Wallin M, Maccioni RB: Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau. Biochim Biophys Acta. 1992 May 22;1121(1-2):97-103. [PubMed Link Image]
  2. Stearns ME, Wang M, Sousa O: Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion. J Cell Sci. 1991 Jan;98 ( Pt 1):55-63. [PubMed Link Image]
  3. Friden B, Rutberg M, Deinum J, Wallin M: The effect of estramustine derivatives on microtubule assembly in vitro depends on the charge of the substituent. Biochem Pharmacol. 1991 Aug 8;42(5):997-1006. [PubMed Link Image]
  4. Burns RG: Stoichiometry of estramustine phosphate binding to MAP2 measured by the disassembly of chick brain MAP2:tubulin microtubules. Cell Motil Cytoskeleton. 1990;17(3):167-73. [PubMed Link Image]
  5. Falconer MM, Vielkind U, Brown DL: Association of acetylated microtubules, vimentin intermediate filaments, and MAP 2 during early neural differentiation in EC cell culture. Biochem Cell Biol. 1989 Sep;67(9):537-44. [PubMed Link Image]
Drug Target 5 [top]
Target 5 ID 2107
Target 5 Name Microtubule-associated protein 1A
Target 5 Synonyms
  1. MAP 1A
  2. Proliferation-related protein p80
Target 5 Gene Name MAP1A
Target 5 Protein Sequence >Microtubule-associated protein 1A 
MDGVAEFSEYVSETVDVPSPFDLLEPPTSGGFLKLSKPCCYIFPGGRGDSALFAVNGFNI
LVDGGSDRKSCFWKLVRHLDRIDSVLLTHIGADNLPGINGLLQRKVAELEEEQSQGSSSY
SDWVKNLISPELGVVFFNVPEKLRLPDASRKAKRSIEEACLTLQHLNRLGIQAEPLYRVV
SNTIEPLTLFHKMGVGRLDMYVLNPVKDSKEMQFLMQKWAGNSKAKTGIVLPNGKEAEIS
VPYLTSITALVVWLPANPTEKIVRVLFPGNAPQNKILEGLEKLRHLDFLRYPVATQKDLA
SGAVPTNLKPSKIKQRADSKESLKATTKTAVSKLAKREEVVEEGAKEARSELAKELAKTE
KKAKESSEKPPEKPAKPERVKTESSEALKAEKRKLIKDKVGKKHLKEKISKLEEKKDKEK
KEIKKERKELKKDEGRKEEKKDAKKEEKRKDTKPELKKISKPDLKPFTPEVRKTLYKAKV
PGRVKIDRSRAIRGEKELSSEPQTPPAQKGTVPLPTISGHRELVLSSPEDLTQDFEEMKR
EERALLAEQRDTGLGDKPFPLDTAEEGPPSTAIQGTPPSVPGLGQEEHVMKEKELVPEVP
EEQGSKDRGLDSGAETEEEKDTWEEKKQREAERLPDRTEAREESEPEVKEDVIEKAELEE
MEEVHPSDEEEEDATKAEGFYQKHMQEPLKVTPRSREAFGGRELGLQGKAPEKETSLFLS
SLTTPAGATEHVSYIQDETIPGYSETEQTISDEEIHDEPEERPAPPRFHTSTYDLPGPEG
AGPFEASQPADSAVPATSGKVYGTPETELTYPTNIVAAPLAEEEHVSSATSITECDKLSS
FATSVAEDQSVASLTAPQTEETGKSSLLLDTVTSIPSSRTEATQGLDYVPSAGTISPTSS
LEEDKGFKSPPCEDFSVTGESEKRGEIIGKGLSGERAVEEEEEETANVEMSEKLCSQYGT
PVFSAPGHALHPGEPALGEAEERCLSPDDSTVKMASPPPSGPPSATHTPFHQSPVEEKSE
PQDFQEADSWGDTKRTPGVGKEDAAEETVKPGPEEGTLEKEEKVPPPRSPQAQEAPVNID
EGLTGCTIQLLPAQDKAIVFEIMEAGEPTGPILGAEALPGGLRTLPQEPGKPQKDEVLRY
PDRSLSPEDAESLSVLSVPSPDTANQEPTPKSPCGLTEQYLHKDRWPEVSPEDTQSLSLS
EESPSKETSLDVSSKQLSPESLGTLQFGELNLGKEEMGHLMQAEDTSHHTAPMSVPEPHA
ATASPPTDGTTRYSAQTDITDDSLDRKSPASSFSHSTPSGNGKYLPGAITSPDEHILTPD
SSFSKSPESLPGPALEDIAIKWEDKVPGLKDRTSEQKKEPEPKDEVLQQKDKTLEHKEVV
EPKDTAIYQKDEALHVKNEAVKQQDKALEQKGRDLEQKDTALEQKDKALEPKDKDLEEKD
KALEQKDKIPEEKDKALEQKDTALEQKDKALEPKDKDLEQKDRVLEQKEKIPEEKDKALD
QKVRSVEHKAPEDTVAEMKDRDLEQTDKAPEQKHQAQEQKDKVSEKKDQALEQKYWALGQ
KDEALEQNIQALEENHQTQEQESLVQEDKTRKPKMLEEKSPEKVKAMEEKLEALLEKTKA
LGLEESLVQEGRAREQEEKYWRGQDVVQEWQETSPTREEPAGEQKELAPAWEDTSPEQDN
RYWRGREDVALEQDTYWRELSCERKVWFPHELDGQGARPHYTEERESTFLDEGPDDEQEV
PLREHATRSPWASDFKDFQESSPQKGLEVERWLAESPVGLPPEEEDKLTRSPFEIISPPA
SPPEMVGQRVPSAPGQESPIPDPKLMPHMKNEPTTPSWLADIPPWVPKDRPLPPAPLSPA
PGPPTPAPESHTPAPFSWGTPEYDSVVAAVQEGAAELEGGPYSPLGKDYRKVXGEREEEG
RAEAPDKSSHXSKVPEARKSHATTEPEQTEPEQREPTPYPDERSFQYADIYEQMMLTGLG
PACPTREPPLGAAGDWPPCLSTKEAAAGRNTSAEKELSSPISPKSLQSDTPTFSYAALAG
PTVPPRXEPGPSMEPSLTPPAVPPRAPILSKGPSPPLNGNILSCSPDRRSPSPKESGRSH
WDDSTSDSELEKGAREQAEKEAQSPSPPHPIPMGSPTLWPETEAHVSPPLXSHLGXARPS
LDFPASAFGFSSLEXAPPQXPSPAEPRSAPCGSLAFSGDRALALAPGPPTRTRYDEYLEV
TKAPSLDSSLPQLPSPSSPGXPLLSNLPRPASPALSEGSSSEATTPVISSVAERFSPSLE
AAEQESGELDPGMEPAAHXLWDLTPLSPAPPASLDLALAPAPSLPGDMGDGILPCHLECS
EAATEKPSPFQVPSEDCAANGPTETSPNPPXPAPAKAENEEAAAXPAWERGAWPEGAERS
SRPDTXLSPEQPVCPXGGSGGPPSSASPEVEAGPQGCXTEPRPHRGELSPSFLNPPLPPS
IDDRDLSTEEVRLVGRGGRRRVGGPGTTGXPXPVTDETPPTSASDSGSSQSDSDVPPETE
ECPSITAEAALDSDEDGDFLPVDKXGGVSGTHHPRPGHDPPPLPQPDXRPSPPRPDVCMA
DPEGLSSESGRXERLRXKEKVQGRVGRRAPGKDKPVSPXRRLXLRGKRSPTPGKGSXDRV
SRXPXRSRSXTSQVTPAEEKDGHSPMSKGLVNGLKAGPXALSSKGSSGAPVYVDLAYIPN
HWSGKTADLDFFRRVRASYYVVSGNDPANGEPSRAVLDALLEGKAQWGENLQVKVTLIPT
HDTEVTREWYQQTHEQQQQLNVLVLASSSTVVMQDESFPACKIEF
Target 5 Number of Residues 2851
Target 5 Molecular Weight 305018
Target 5 Theoretical pI 4.57
Target 5 GO Classification Not Available
Target 5 General Function Replication, recombination and repair
Target 5 Specific Function Structural protein involved in the filamentous cross- bridging between microtubules and other skeletal elements
Target 5 Pathways Not Available
Target 5 Reactions Not Available
Target 5 Pfam Domain Function Not Available
Target 5 Signals
  • None
Target 5 Transmembrane Regions
  • None
Target 5 Essentiality Non-Essential
Target 5 GenBank ID Protein 1790878 Link Image
Target 5 UniProtKB/Swiss-Prot ID P78559 Link Image
Target 5 UniProtKB/Swiss-Prot Entry Name MAP1A_HUMAN Link Image
Target 5 PDB ID Not Available
Target 5 Cellular Location Not Available
Target 5 Gene Sequence >8418 bp 
ATGGACGGCGTGGCTGAGTTCTCCGAGTATGTCTCTGAGACTGTGGACGTGCCATCCCCA
TNTGACCTACTAGAGCCCCCCACCTCAGGGGGCTTCCTCAAGCTCTCCAAGCCTTGTTGC
TACATCTTCCCAGGTGGTCGNGGGGACTCTGCCCTCTTTGCTGTCAATGGTTTCAACATC
CTGGTGGATGGTGGCTCTGATCGCAAGTCCTGTTTGTGGAAGCTGGTACGGNACTTGGAC
CGCATTGACTCGGTGCTACTCACACACATTGGGGCAGACAACCTGCCAGGCATCAATGGA
CTACTGCAGCGCAAAGTGGCAGAGCTAGAGGAGGAGCAGTCCCAGGGCTCTAGCAGTTAC
AGCGACTGGGTGAAGAACCTTATCTCTCCTGAGCTTGGAGTTGTCTTTTTCAACGTGCCT
GAGAAGCTGCGGCTTCCTGATGCCTCCCGGAAAGCCAAGCGTAGCATTGAGGAGGCCTGC
CTCACTCTGCAGCACTTAAACCGCCTGGGCATCCAGGCTGAGCCTCTATATCGTGTGGTC
AGCAATACCATTGAGCCACTGACCCTCTTCCACAAAATGGGTGTGGNCCGGCTGGACATG
TATGTCCTCAACCCTGTCAAGGACAGCAAGGAGATGCAGTTCCTCATGCANAAGTGGGCA
GGCAATAGTAAAGCCAAGACAGGCATCGTGCTGCCCAATGGGAAGGAGGCTGAGATCTCC
GTGCCCTACCTTACCTCTATCACTGCTCTGGTGGTCTGGCTACCAGCCAATCCCACTGAG
AAGATTGTGCGTGTGCTTTTTCCAGGAAATGCTCCCCAAAACAAGATCTTGGAGGGCCTA
GAAAAGCTTCGGCATCTGGACTTCCTGCGTTACCCTGTGGCCACGCAGAAGGACCTGGCT
TCTGGGGCTGTGCCTACCAACCTCAAGCCCAGCAAAATCAAACAGCGGGCTGATAGCAAG
GAGAGCCTCAAAGCCACTACCAAGACGNCCGTGAGCAAGTTGTCCACACGGGAGGAGGTG
GTAGAAGAGGGAGCCAAGGAGGCACGTTCAGAGCTGTCCAAGGAGTTATCCAAGACAGAG
AAGAAGGCNCAAGAGTCATCTGAGAAGCCCCCAGAGAAGCCTNCCAAGCCTGAGAGGGTG
AAGACAGAGTCAAGTGAGGCACTGNAGGCAGAGAAGCGAAAGCTGATCAAAGACAAGGTA
GGGAAAAAGCACCTTAAAGAAAAGATATCNAAGCTGGAAGAAAAAAAAGACAAGGAGANA
AAAGAGATCCCANAGGAGAGGAAAGAGCTCAAGAAGGATGAAGGAAGGAAGGAGGAGAAG
AAGGATNCCAAGAAGGAGGAGAAGAGGAAAGATACCAAACCTGAGCTCAAGAAGATTTCC
AAGCCAGACCTAAAGCCCTTTACTCCTGAGGTACGTAAGACCCTCTATAAAGCCAAGGTC
CCTGGAAGAGTCCNAATAGACAGGAGCCGTGCTATCCGTGGGGAGAAGGAGCTGTCTTCT
GAGCCCCAGACACCCCCAGCCCAGAAGGGAACTGTACCACTCCCAACCATCAGTGGGCAC
AGGGAGCTGGTCCTATCCTCACCAGAGGACCTCACACAGGACTTTGAGGAGATGAAGCGT
GAGGAGAGGGCTTTGCTGGCTGAACAAAGGGACACAGGACTAGGAGATAAGCCATTCCCT
CTAGACACTGCAGAGGAGGGACCCCCAAGTACAGCTATCCAGGGAACACCACCCTCTGTT
CCAGGGCTGGGACAAGAAGAACATGTGATGAAGGAGAAAGAGCTTGTCCCAGAGGTCCCT
GAGGAACAAGGCAGCAAGGACAGAGGCCTAGACTCTGGGGCTGAAACAGAGGAAGAGAAA
GATACCTGGGAGGAAAAGAAGCAGAGGGAAGCAGAGAGGCTCCCAGACAGAACAGAAGCC
AGAGAGGAAAGTGNACCTGNAGTAAAGGAGGATGTGATAGAAAAGGCTGAGTTAGAAGAA
ATGGAGGAGGTACACCCTTCAGATGAGGAGGAAGAGGACGCGACCCNANCTGAGGGTTTT
TACCCCNAACATATGCAGGAACCCTTGNAGGTAACTCCAAGGAGCCGGGAGGCTTTTGGG
GGTCGGGAATTGGGACTCCAGGGCAAGGCCCCTGAGAAGGAGACCTCGTTATTCCTAAGC
AGCCTGACCACACCTGCAGGAGCCACTGAGCATGTCTCTTACATCCAGGATGAGACAATC
CCTGGCTACTCAGAGACTGAGCAGACCATCTCAGATGAGGAGATCCATGATGAGCCGGAG
GAGCGCCCAGCTCCACCCAGATTTCATACAAGTACATATGACCTGCCCGGGCCTGAAGGT
GCTGGCCCATTCGAAGCCAGCCAACCTGCCGATAGTGCTGTTCCTGCTACCTCTGGCAAA
GTCTATGGAACGCCAGAGACTGAACTCACCTACCCCACTAACATAGTGGCTGCCCCTTTG
GCTGAAGAGGAACATGTGTCCTCGGCCACTTCAATCACTGAGTGTGACAAACTTTCTTCC
TTTGCCACATCAGTGGCTGAGGACCAATCTGTGGCCTCACTTACAGCTCCCCAGACAGAG
GAGACAGGCAAGAGCTCCCTGCTGCTTGACACAGTCACAAGCATCCCTTCCTCCCGTACT
GAAGCTACGCAGGGCTTGGACTATGTGCCATCAGCTGGTACCATCTCACCCACCTCCTCA
CTGGNAGAAGANAAGGGCTTCANATCACCACCCTGTGAGGACTTCTCTGTGACTGGGGAG
TCAGAGAAGAGAGGAGAGATCATAGGGAAAGGCTTGTCTGGAGAGAGAGCTGTGGAAGAG
GAAGAGGAGGAGACAGCAAACGTAGAGATGTCTGAGAAACTTTGNAGTCAATNTGGAACT
CCAGTGTTTAGTGCCCCTGGGNATGCCCTACATCCAGGAGAACCAGCCCTTGGAGAAGCA
GAGGAGCGGTGCCTTAGCCCAGATGACAGCACAGTGAAGATGGCTTCTCCTCCACCATCT
GGCCCACCCAGTGCCACCCACACACCCTTTCATCAGTCCCCAGTGGAAGAAAAGTCTGAG
CCCCAAGACTTCAAGGAGGCAGACTCCTGGGGAGACACTAAGCGCACACCAGGTGTGGGC
AAAGAAGATGCTGCTGAGGAGACAGTCAAGCCAGGGCCTGAAGAGGGCACACTAGAGAAG
GAAGAGAAAGTTCCTCCTCCCAGGAGCCCCCAGGCCCAGGAAGCACCTGTCAACATTGAT
GAGGGGCTTACAGGCTGTACCATTCAACTGTTGCCAGCACAGGATAAAGCAATAGTCTTT
GAGATTATGGAGGCAGGAGAGCCCACAGGCCCAATTCTGGGAGCAGAAGCCCTTCCCGGA
GGTTTGAGGACTTTACCCCAAGAACCTGGCAAACCTCAGAAAGATGAGGTGCTCAGATAT
CCTGACCGAAGCCTCTCTCCTGAAGATGNAGAATCCCTCTCTGTCCTCAGCGTGCCCTCC
CCAGACACTGNCANCCAAGAGCCTACCCCCAAGTCTCCCTGTGGNCTGANAGAACAGNAC
CTACACAAAGACCGGTGGNCAGAGGTATCTCCAGAAGACACCCAGTCACTTTCTCTGTCA
GAAGAGAGTCCCAGCAAGGAGACCTCCCTGGATGTCTCTTCTAAGCAGCTCTCTCCAGAA
AGCCTTGGCACCCTCCAGTTTGGGGAACTAAACCTTGGGAAGGAAGAAATGGGGCATCTG
ATGCAGGCCGAGGATACCTCTCACCACACAGCTCCCATGTCTGTTCCAGAGCCCCATGCA
GCCACAGCGTCACCTCCCACAGATGGGACAACTCGATACTCTGCACAGACAGACATCACA
GATGACAGCCTTGACAGGAAGTCACCTGCCAGCTCATTCTCTCACTCTACACCTTCAGGA
AATGGGAAGTACTTACCTGGGGCGATCACAAGCCCTGATGAACACATTCTGACANCTGAT
AGCTCCTTCTCCAAGAGTCCTGAGTCTTTGNCAGGCCCTGCCTTGGNGGACATTGCCATA
AAGTGGGAAGATAAAGTTCCAGGGTTGAAAGACAGAACCTCAGAACAGAAGAAGGAACCT
GAGCCAAAGGATGAAGTTTTACAGCAGAAAGACAAAACTCTGGAGCACAAGGAGGTGGTA
GAGCCGAAGGATACAGCCATCTATCAGAAAGATGAGGCTCTGCATGTAAAGAATGAGGCT
GTGAAACAGCAGGNTAAGGCTTTAGAACAAAAGGGCAGAGACTTAGAGCAANAAGACACA
GCCCTAGAACAGAAGGACAAGGCCCTGGAACCAAAAGACAAAGACTTAGAANAAAANGAC
AAGGCCCTGGAACAGAAGGATAAGATTCCAGNAGAGAAAGACAAAGCCTTAGAACAAAAG
GATACAGCCCTGGAACAGAAGGACAAGGCCCTGGAACCAAAAGATAAAGACTTGGAACAA
AAGGACAGGGTCCTAGAACAGAAGGAGAAGATCCCAGAAGAGAAAGACAAAGCCTTAGAT
CAAAAAGTCAGAAGTGTTGAACATAAGGCTCCGGAGGACACGGTCGCTGAAATGAAGGAC
AGAGACCTAGAACAGACAGACAAAGCCCCTGAACAGAAACACCAGGCCCAGGAACAAAAG
GATAAAGTCTCAGAAAAGAAGGATCAGGCCTTAGAACNCAAATACTGGGCTTTGGGACAG
AAGGATGAAGCCCTGGAACNAAACATTCAGGCTCTGGAAGAGAACCACCAAACTCAGGAG
CAGGAGAGCCTAGTGCAGGAGGATAAAACCAGGAAACCNAAGATGCTAGAGGAAAAATCC
CCAGAAAAGGTCAAGGCCATGGAAGAGAAGTTAGAAGCTCTTCTGGAGAAGACCNNAGCT
CTGGGCCTGGAAGAGAGCCTAGTGCAGGAGGGCAGGGCCAGAGAGCAGGAAGAAAAGTAC
TGGAGGGGGCAGGATGTGGTCCAGGAGTGTCAAGAAACATCTCCTNCCAGAGAGGAGCCG
GCTGGAGAACAGAAAGAGCTTNCCCCGGCATGGGAGGACACATCTCCTGAGCAGGACAAT
AGGTATTGGAGGGGCAGAGAGGATGTGTCCTTGGAACAGGACACATACTGGAGGGAGCTA
AGCTGTGAGCGGAAGGTCTGGTTCCCTCACGAGCTGGATGTCCAGGGGGCCCGCCCACAC
TACACTGANGAACGGGAAAGCACTTTCCTAGATGAGGGCCCAGATGATGAGCAAGAAGTA
CCCCTGCGGGAACACGCAACCCGGAGCCCCTGGGCCTCAGACTTCAAGGATTTCCAGGAA
TCCTCACCACAGAAGGGGCTAGAGGTGGAGCGCTGGCTTGCTGAATCACCAGTTGGGTTG
CCACCAGAGGAAGAGGACAAACTGACCCGCTCTCCCTTTGAGATCATCTCCCCTCCAGCT
TCCCCACCTGAGATGGTTGGACAAAGGGTTCCTTCAGCCCCAGGACAAGAGAGTCCTATC
CCAGACCCTAAGCTCATGCCACACATGAAGAATGAACCCACTACTCCCTCATGGCTGGCT
GANATCCCACCCTGGGTGCCCAAGGNCAGACCCCTCCCCNCTGCACCCCTCTCCCCAGCT
CCTGGTCCCCCCACACCTGCCCCGGAATCCCATACTCCTGCACCCTTCTCTTGGGGCACA
CCCGAGTATGACAGTGTGGTGGCTGCAGTACAGGAGGGGGCAGCTGAGTTGGAAGGTGGN
CCATACTCCCCCCTGGGGAAGGACTACCGCAAGGTTGANGGGGAAAGGGAAGAAGAAGGT
AGGGCTGAGGCTCCTGACAAAAGCTCACACAGNTCAAAGGTACCAGAGGCCAGGAAAAGC
CATGCCACCACGGAGCCTGAGCAGACTGAGCCGGAGCAGAGAGAGCCCACACCCTATCCT
GATGAGAGAAGCTTTCAGTATGCAGACATCTATGAGCAGATGATGCTTACTGGGCTTGGC
CCTGCATGCCCCACTAGAGAGCCTCCACTTGGAGCAGCTGGGGATTGGCCCCCATGCCTC
TCAACCAAGGAGGCAGCTGCCGGCCGAAACACATCTGCAGAGAAGGAGCTTTCATCTCCT
ATCTCACCCAAGAGCCTCCAGTCTGACACTCCAACCTTCAGCTATGCAGCCCTGGCAGGA
CCCACTGTACCCCCAAGGNCAGAGCCAGGGCCAAGTATGGAGCCCAGNCTCACCCCACCT
GCAGTTCCCCCCCGTGCTCCTATCCTGAGCAAAGGCCCAAGCCCCCCTCTTAATGGTAAC
ATCCTGAGCTGCAGCCCAGATAGGAGGTCCCCATCCCCCAAGGAATCAGGNCGGAGTCAC
TGGGATGACAGCACTAGTGACTCAGAACTGGAGAAGGGGGCTCGGGAACAGGCAGAAAAA
GAGGCCCAATCCCCAAGTCCTCCTCACCCCATTCCTATGGGGTCCCCCACATTATGGCCA
GAAACTGAGGCACATGTTAGCCCTCCCTTGGNCTCACACCTGGGGNCTGCCCGACCCAGT
CTGGACTTCCCTGCTTCAGCCTTTGGCTTCTCCTCATTGGANNCAGCTCCCCCACAGNTG
CCCTCTCCAGCTGAACCCCGCTCGGCACCCTGTGGCTCCCTTGCCTTCTCTGGGGATCGA
GCTCTGGCTCTGGCTCCAGGACCCCCCACCAGAACCCGGTATGATGAATACCTGGAAGTG
ACCAAGGCCCCCAGCCTGGATTCCTCACTGCCCCAGCTCCCATCACCCAGTTCTCCTGGG
GNCCCTCTCCTCTCCAATCTGCCACGACCTGCCTCACCAGCCCTGTCTGAGGGCTCCTCC
TCTGAGGCTACCACGCCTGTGATTTCAAGTGTGGCGGAGCGCTTCTCTCCAAGCCTTGAG
GCTGCAGAACAGGAGTCTGGAGAGCTGGACCCAGGAATGGAACCAGCTGCCCACAGNCTC
TGGGACCTCACTCCTCTGAGCCCAGCACCCCCAGCTTCACTGGACTTGGCCCTAGCTCCA
GCTCCAAGCCTGCCTGGAGACATGGGTGATGGCATCCTGCCGTGCCACCTGGAGTGCTCA
GAGGCAGCCACGGAGAAGCCAAGCCCCTTCCAGGTTCCCTCTGAGGATTGTGCAGCCAAT
GGCCCAACTGAAACCAGCCCTAACCCCCCAGNCCCTGCCCCAGCCAAGGCTGAAAATGAA
GAGGCTGCGGCTTNCCCTGCCTGGGAACGTGGGGCCTGGCCTGAAGGAGCTGAGAGGAGC
TCCCGGCCTGACACANTGCTCTCCCCTGAGCAGCCAGTGTGTCCTNCAGGGGGCTCCGGG
GGCCCACCCAGCAGTGCCTCTCCTGAGGTCGAAGCTGGGCCCCAGGGATGTNCCACTGAG
CCTCGGCCCCATCGTGGGGAGCTCTCCCCATCCTTCCTGAACCCACCTCTGCCCCCATCC
ATAGATGATAGGGACCTCTCAACTGAGGAAGTTCGGCTAGTAGGAAGAGGGGGGCGGCGC
CGGGTAGGGGGGCCAGGGACCACTGGGGNNCCATGNCCTGTGACTGATGAGACACCCCCN
ACATCAGCCAGTGACTCAGGCTCCTCACAGTCAGATTCTGATGTNCCGCCAGAAACTGAG
GAGTGTCCGTCCATCACAGCTGAGGCAGCCCTCGACTCAGATGAAGATGGAGACTTCCTA
CCTGTGGACAAANCTGGGGGTGTCAGTGGTACTCACCACCCCAGGCCTGGCCATGACCCA
CCTCCTCTCCCACAGCCAGACCNCCGCCCATCCCCTCCCCGCCCTGATGTGTGCATGGCT
GACCCCGAGGGGCTCAGNTCAGAGTCTGGGAGAGNAGAGAGGCTACGGNAGAAGGAAAAG
GTTCAGGGGCGAGTAGGGCGTAGGGCCCCAGGTAAGGACAAGCCAGTGTCCCCTGNACGG
CGTCTGGNTCTTCGGGGAAAACGCTCACCCACCCCTGGTAAAGGGTCTGNAGATCGAGTA
TCCCGGNCCCCANCTCGATCACGNAGTANCACAAGCCAGGTCACCCCAGCAGAGGAAAAG
GATGGACACAGCCCCATGTCCAAAGGNCTAGTCAATGGACTCAAGGCAGGACCANTGGCC
TTGAGTTCCAAGGGCAGCTCTGGTGCCCCTGTATATGTGGATCTCGCCTACATCCCGAAT
CATTGGAGTGGCAAGACTGCTGACCTNGACTTCTTCCGTCGAGTGCGTGCATCCTACTAT
GTGGTCAGTGGGAATGACCCTGCCAATGGCGAGCCAAGCCGGGCTGTGCTGGATGCCCTG
CTGGAGGGCAAGGCCCAGTGGGGGGAGAATCTTCAGGTGAAGGTGACTCTGATCCCTACT
CATGACACGGAGGTGACTCGTGAGTGGTACCAACAAACTCATGAGCAGCAGCAACAACTG
AATGTCCTGGTCCTGGCTAGCAGCAGCACCGTGGTGATGCAGGATGAGTCCTTCCCTGCC
TGCAAGATTGAGTTCTGA
Target 5 GenBank Gene ID
Target 5 GeneCard ID MAP1A Link Image
Target 5 GenAtlas ID MAP1A Link Image
Target 5 HGNC ID HGNC:6835 Link Image
Target 5 Chromosome Location 15
Target 5 Locus 15q13-qter
Target 5 SNPs SNPJam Report Link Image
Target 5 General References
  1. Fukuyama R, Rapoport SI: Brain-specific expression of human microtubule-associated protein 1A (MAP1A) gene and its assignment to human chromosome 15. J Neurosci Res. 1995 Apr 15;40(6):820-5. [PubMed Link Image]
  2. Fink JK, Jones SM, Esposito C, Wilkowski J: Human microtubule-associated protein 1a (MAP1A) gene: genomic organization, cDNA sequence, and developmental- and tissue-specific expression. Genomics. 1996 Aug 1;35(3):577-85. [PubMed Link Image]
Target 5 Drug References
  1. Stearns ME, Wang M, Sousa O: Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion. J Cell Sci. 1991 Jan;98 ( Pt 1):55-63. [PubMed Link Image]

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.